The findings endorse the potential of targeting S100A9 as a therapeutic approach and underscore the effectiveness of tasquinimod in inhibiting SCLC progression, modulating the immune tumor microenvironment, and enhancing overall survival. The gene discussed is S100A9; the disease is neoplasm.